Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Canada invests in Resilience’s Ontario facility

by Rick Mullin
May 22, 2021 | A version of this story appeared in Volume 99, Issue 19

 

The government of Canada will invest about $165 million in National Resilience’s facility in Mississauga, Ontario, to improve its pandemic preparedness. The investment, through Canada’s Strategic Innovation Fund, will go toward modernizing and expanding the former Therapure Biopharma, which Resilience acquired last year. The 12,800 m2 facility provides analytical development, manufacturing, and fill-and-finish services for therapeutics and vaccines. Resilience was formed in 2020 as a contract manufacturing organization focused on innovative technologies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.